Once this is determined, it would be tempting to be able to stratify patients based on FAM46C/FNDC3A expression levels or mutational status, as this could enable us to predict cancer responsiveness to autophagy inhibitors and enable tailored and personalised therapies. The gene discussed is FNDC3A; the disease is cancer.